Changes in levels of biomarkers of exposure and biological effect in a controlled study of smokers switched from conventional cigarettes to reduced-toxicant-prototype cigarettes

Regulatory Toxicology and Pharmacology

Volumn 72, Issue 2, 2015, Pages 273-291

  Shepperd, Christopher J ^a   Newland, Nik ^a   Eldridge, Alison ^a   Haswell, Linsey ^a   Lowe, Frazer ^a   Papadopoulou, Ermioni ^a   Camacho, Oscar ^a   Proctor, Christopher J ^a   Graff, Don ^b   Meyer, Ingo ^c  

^a BRITISH AMERICAN TOBACCO   (United Kingdom)

^b CELERION   (United States)

^c MPS Hamburg GmbH   (Germany)

Author keywords

Biomarker of biological effect; Biomarker of effective dose; Biomarker of exposure; Modified risk tobacco product; MRTP; Potential reduced exposure product; PREP; Reduced toxicant prototype cigarettes; Smoking; Tobacco smoke toxicants

Indexed keywords

ACROLEIN; AROMATIC AMINE; AROMATIC HYDROCARBON; BIOLOGICAL MARKER; CARBON MONOXIDE; CARBONYL DERIVATIVE; CIGARETTE SMOKE; COAL TAR; CROTONALDEHYDE; NICOTINE; NITROSAMINE; DANGEROUS GOODS;

ADULT; ARTICLE; BLOOD SAMPLING; CHEMICAL ANALYSIS; CHEMICAL COMPOSITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTICULATE MATTER; PRIORITY JOURNAL; REDUCED TOXICANT-PROTOTYPE CIGARETTE; SINGLE BLIND PROCEDURE; SMOKING; SMOKING HABIT; TOBACCO CONSUMPTION; URINALYSIS; ANALYSIS; BLOOD; DANGEROUS GOODS; ENVIRONMENTAL EXPOSURE; MIDDLE AGED; QUESTIONNAIRE; TOBACCO; TOXICITY; URINE; YOUNG ADULT;

NICOTIANA TABACUM;

ADULT; BIOMARKERS; ENVIRONMENTAL EXPOSURE; FEMALE; HAZARDOUS SUBSTANCES; HUMANS; MALE; MIDDLE AGED; SMOKING; SURVEYS AND QUESTIONNAIRES; TOBACCO PRODUCTS; YOUNG ADULT;

EID: 84929410502     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2015.04.016     Document Type: Article

References (67)

1. Agurell E., Stensman C. Salmonella mutagenicity of three complex mixtures assayed with the microsuspension technique. A WHO/IPCS/CSCM study. Mutat. Res. 1992, 276:87-91.
2. Blann A.D., Steele C., McCollum C.N. The influence of smoking and of oral and transdermal nicotine on blood pressure, and haematology and coagulation indices. Thromb. Haemost. 1997, 78:1093-1096.
3. Branton P.J., McAdam K.G., Duke M.G., et al. Use of classical adsorption theory to understand the dynamic filtration of volatile toxicants in cigarette smoke by active carbons. Absorp. Sci. Technol. 2011, 29:117-138.
4. Branton P.J., McAdam K.G., Winter D.B., et al. Reduction of aldehydes and hydrogen cyanide yields in mainstream cigarette smoke using an amine functionalised ion exchange resin. Chem. Cent. J. 2011, 5(1):15.
5. Burns D.M., Dybing E., Gray N., Hecht S., Anderson C., Sanner T., O'Connor R., Djordjevic M., Dresler C., Hainaut P., et al. Mandated lowering of toxicants in cigarette smoke: a description of the World Health Organization TobReg proposal. Tob. Control 2008, 17:132-141.
6. Charles F.K., Ashley M., Shepperd C.J., Clayton P., Errington G.A. Robust method for estimating human smoked cigarette yields from filter analysis data. Beit Tabakforsch Int 2009, 23:232-243.
7. Chehne F., Oguogho A., Lupattelli G., Palumbo B., Sinzinger H. Effect of giving up cigarette smoking and restarting in patients with clinically manifested atherosclerosis. Prostaglandins Leukot. Essent. Fatty Acids 2002, 67(5):333-339.
8. Chelland Campbell S., Moffatt R.J., Stamford B.A. Smoking and smoking cessation - the relationship between cardiovascular disease and lipoprotein metabolism: a review. Atherosclerosis 2008, 201(2):225-235.
9. Committee on Scientific Standards for Studies on Modified Risk Tobacco Products, Board on Population Health and Public Health Practice, Institute of Medicine, 2011. Scientific Standards for Studies on Modified Risk Tobacco Products. The National Academies Press, Washington D.C.
10. Crooks I., Scott K., Dalrymple A., Dillon D., Meredith C. The combination of two novel tobacco blends and filter technologies to reduce the in vitro genotoxicity and cytotoxicity of prototype cigarettes. Regul. Toxicol. Pharmacol. 2015, 71:507-514.
11. Cunningham F.H., Fiebelkorn S., Johnson M., Meredith C. A novel application of the margin of exposure approach: segregation of tobacco smoke toxicants. Food Chem. Toxicol. 2011, 49:2921-2933.
12. Deo R., Khera A., McGuire D.K., Murphy S.A., Meo Neto Jde P., Morrow D.A., de Lemos J.A. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J. Am. Coll. Cardiol. 2004, 44(9):1812-1818.
13. Ding Y.S., Blount B.C., Valentin-Blasini L., Applewhite H.S., Xia Y., Watson C.H., Ashley D.L. Simultaneous determination of six mercapturic acid metabolites of volatile organic compounds in human urine. Chem. Res. Toxicol. 2009, 22:1018-1025.
14. Dittrich D., et al. Approaches for the design of reduced toxicant emission cigarettes. SpringerPlus 2014, 2:374.
15. Doll R., Peto R., Wheatley K., Gray R., Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994, 309(6959):901-911.
16. Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under Section 904(a)(3) of the Federal Food, Drug & Cosmetic Act. 2012. FDA Center for Tobacco Products. Washington, DC. http://www.fda.gov/downloads/TobaccoProducts/GuidanceComplianceRegulatoryInformation/UCM297828.pdf.
17. Flores L., Vidal M., Abian J., Cases A., Campistol J.M., Clària J., Lario S., Esmatjes E. The effects of smoking and its cessation on 8-epi-PGF2alpha and transforming growth factor-beta 1 in Type 1 diabetes mellitus. Diabet. Med. 2004, 21(3):285-289.
18. Fowles J., Dybing E. Application of toxicological risk assessment principles to the chemical constituents of cigarette smoke. Tob. Control 2003, 12(4):424-430.
19. Frohlich M., Sund M., Lowel H., Imhof A., Hoffmeister A., Koenig W. Independent association of various smoking characteristics with markers of systemic inflammation in men. Eur. Heart J. 2003, 24:1365-1372.
20. Frost-Pineda K., Liang Q., Liu J., Rimmer L., Jin Y., Feng S., Kapur S., Mendes P., Roethig H., Sarkar M. Biomarkers of potential harm among adult smokers and nonsmokers in the total exposure study. Nicotine Tob. Res. 2011, 13(3):182-193.
21. Goniewicz M.L., et al. Elimination kinetics of the tobacco-specific biomarker and lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Cancer Epidemiol. Biomarkers Prev. 2009, 18(12):3421.
22. Gregg E.O., Minet E., McEwan M. Urinary biomarkers of smokers' exposure to tobacco smoke constituents in tobacco products assessment: a fit for purpose approach. Biomarkers 2013, 18(6):467-486.
23. Gross M.D., Bielinski S.J., Suarez-Lopez J.R., Reiner A.P., Bailey K., Thyagarajan B., Carr J.J., Duprez D.A., Jacobs D.R. Circulating soluble intercellular adhesion molecule 1 and subclinical atherosclerosis: the Coronary Artery Risk Development in Young Adults Study. Clin. Chem. 2012, 58(2):411-420.
24. Gyorffy E., Anna L., Kovacs K., Rudnai P., Schoket B. Correlation between biomarkers of human exposure to genotoxins with focus on carcinogen-DNA adducts. Mutagenesis 2008, 23:1-18.
25. Hammet C.J.K., Prapavessis H., Baldi J.C., et al. Variation in blood levels of inflammatory markers related and unrelated to smoking cessation in women. Prev. Cardiol. 2007, 10:68-75.
26. Hammond D., Fong G.T., McNeill A., Borland R., Cummings K.M. Effectiveness of cigarette warning labels in informing smokers about the risks of smoking: findings from the International Tobacco Control (ITC) Four Country Survey. Tob. Control 2006, 15(Suppl. III). iii19-iii25.
27. Haswell L.E., Papadopoulou E., Newland N., Shepperd C.J., Lowe F.J. A cross-sectional analysis of candidate biomarkers of biological effect in smokers, never-smokers and ex-smokers. Biomarkers 2014, 19(5):356-376.
28. Hata Y., Nakajima K. Life-style and serum lipids and lipoproteins. J. Atheroscler. Thromb. 2000, 7(4):177-197.
29. Hatsukami D.K., Benowitz N.L., Rennard S.I., Oncken C., Hecht S.S. Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob. Res. 2006, 8(4):600-622.
30. Hatsukami D.K., Hanson K., Briggs A., et al. Clinical trials methods for evaluation of potential reduced exposure products. Cancer Epidemiol. Biomarkers Prev. 2009, 18(12):3143-3195.
31. Huang R.Y., Li M.Y., Hsin M.K., Underwood M.J., Ma L.T., Mok T.S., Warner T.D., Chen G.G. 4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A2 and its receptor. Oncogene 2011, 30(1):106-116.
32. International Agency for Research on Cancer IARC Handbook of cancer prevention, volume 11, Reversal of risk after quitting smoking 2007, WHO Press, Geneva.
33. Kado N.Y., Langley D., Eisenstadt E. A simple modification of the Salmonella liquid-incubation assay. Increased sensitivity for detecting mutagens inhuman urine. Mutat. Res. 1983, 121:25-32.
34. Kavvadias D., Scherer G., Urban M., et al. Simultaneous determination of four tobacco-specific N-nitrosamines (TSNA) in human urine. J. Chromatogr. B 2009, 877(11-12):1185-1192.
35. Kusano K.F., Nakamura K., Kusano H., Nishii N., Banba K., Ikeda T., Hashimoto K., Yamamoto M., Fujio H., Miura A., Ohta K., Morita H., Saito H., Emori T., Nakamura Y., Kusano I., Ohe T. Significance of the level of monocyte chemoattractant protein-1 in human atherosclerosis. Circ. J. 2004, 68(7):671-676.
36. Lao X.Q., Jiang C.Q., Zhang W.S., et al. Smoking, smoking cessation and inflammatory markers in older Chinese men: the Guangzhou BioBank cohort study. Atherosclerosis 2009, 203:304-310.
37. Lewalter J., Gries W. Haemoglobin adducts of aromatic amines: Aniline, o-, m- and p-toluidine, o-anisidine, p-chloroaniline, alpha- and beta-naphthylamin, 4-aminodiphenyl, benzidine, 4,4'-diaminodiphenylmethane, 3,3'-dichlorobenzidine. Biomonitoring Methods 2000, vol. 7:191-219. Wiley-VCH, Weinheim.
38. Liu C., Degrandpre Y., Porter A., et al. The use of a novel tobacco treatment process to reduce toxicant yields in cigarette smoke. Food Chem. Toxicol. 2011, 49(9):1904-1917.
39. Lowe F.J., Gregg E.G., McEwan M. Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers. Clin. Chem. Lab. Med. 2009, 47:311-320.
40. Lowe F.J., Luettich K., Gregg E.O. Lung cancer biomarkers for the assessment of modified risk tobacco products: an oxidative stress perspective. Biomarkers 2013, 18(3):183-195.
41. McAdam K.G., Gregg E.O., Liu C., et al. The use of a novel tobacco-substitute sheet and smoke dilution to reduce toxicant yields in cigarette smoke. Food Chem. Toxicol. 2011, 49(8):1684-1696.
42. Modified Risk Tobacco Products Applications (Draft Guidance for Industry) 2012. FDA Center for Tobacco Products. Washington, DC. http://www.fda.gov/downloads/TobaccoProducts/GuidanceComplianceRegulatoryInformation/UCM297751.pdf.
43. Morrow J.D. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler. Thromb. Vasc. Biol. 2005, 25(2):279-286.
44. Morrow J.D., Frei B., Longmire A.W., Gaziano J.M., Lynch S.M., Shyr Y., Strauss W.E., Oates J.A., Roberts L.J. Increase in circulating products of lipid peroxidation (f2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N. Engl. J. Med. 1995, 332:1198-1203.
45. Nowark J., Murray J.J., John M.D., FitzGerald G.A. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation 1987, 76:6-14.
46. Oguogho A., Lupattelli G., Palumbo B., Sinzinger H. Isoprostanes quickly normalize after quitting cigarette smoking in healthy adults. Vasa 2000, 29(2):103-105.
47. Ohsawa M., Okayama A., Nakamura M., et al. CRP levels are elevated in smokers but unrelated to the number of cigarettes and are decreased by long-term smoking cessation in male smokers. Prev. Med. 2005, 41:651-656.
48. Piemonti L., Calori G., Lattuada G., Mercalli A., Ragogna F., Garancini M.P., Ruotolo G., Luzi L., Perseghin G. Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals. Diabetes Care 2009, 32(11):2105-2110.
49. Rahman I. Oxidative stress in pathogenesis of chronic obstructive pulmonary disease: cellular and molecular mechanisms. Cell Biochem. Biophys. 2005, 43(1):167-188.
50. Ramsauer B., Sterz K., Hagedorn H.W., Engl J., Scherer G., McEwan M., Errington G., Shepperd J., Cheung F. A liquid chromatography/tandem mass spectrometry (LC-MS/MS) method for the determination of phenolic polycyclic aromatic hydrocarbons (OH-PAH) in urine of non-smokers and smokers. Anal. Bioanal. Chem. 2011, 399:877-889.
51. Rangemark C., Ciabattoni G., Wennmalm A. Excretion of Thromboxane metabolites in healthy women after cessation of smoking. Atherosclerosis 1993, 13:777-782.
52. Rickert W.S., Collishaw N.E., Bray D.F., Robinson J.C. Estimates of maximum or average cigarette tar, nicotine, and carbon monoxide yields can be obtained from yields under standard conditions. Prev. Med. 1986, 15:82-91.
53. Riedel K., Scherer G., Engl J., Hagedorn H.W., Tricker A.R. Determination of three carcinogenic aromatic amines in urine of smokers and nonsmokers. J. Anal. Toxicol. 2006, 30:187-195.
54. Roethig H.J., Zedler B.K., Kinser R.D., Feng S., Nelson B.L., Liang Q. Short-term clinical exposure evaluation of a second-generation electrically heated cigarette smoking system. J. Clin. Pharmacol. 2007, 47:518-530.
55. Roethig H.J., Feng S., Liang Q., Liu J., Rees W.A., Zedler B.K. A 12-month, randomized, controlled study to evaluate exposure and cardiovascular risk factors in adult smokers switching from conventional cigarettes to a second-generation electrically heated cigarette smoking system. J. Clin. Pharmacol. 2008, 48(5):580-591.
56. Saareks V., Ylitalo P., Alanko J., Mucha I., Riutta A. Effects of smoking cessation and nicotine substitution on systemic eicosanoid production in man. Naunyn Schmiedebergs Arch Pharmacol. 2001, 363(5):556-561.
57. Sarkar M., Kapur S., Frost-Pineda K., Feng S., Wang J., Liang Q., Roethig H. Evaluation of biomarkers of exposure to selected cigarette smoke constituents in adult smokers switched to carbon-filtered cigarettes in short-term and long-term clinical studies. Nicotine Tob. Res. 2008, 10(12):1761-1772.
58. Scherer G., Urban M., Hagedorn H.W., et al. Determination of two mercapturic acids related to crotonaldehyde in human urine: influence of smoking. Hum. Exp. Toxicol. 2007, 26(1):37-47.
59. Scherer G., Newland K., Papadopoulou E., Minet E. A correlation study applied to biomarkers of internal dose and biomarkers of effective dose for acrylonitrile and 4-aminobiphenyl in smokers. Biomarkers 2014, 19(4):291-301.
60. Shepperd C.J., Eldridge A.C., Camacho O.M., McAdam K., Proctor C.J., Meyer I. Changes in levels of biomarkers of exposure observed in a controlled study of smokers switched from conventional to reduced toxicant prototype cigarettes. Regul. Toxicol. Pharmacol. 2013, 66(1):147-162.
61. Shepperd C.J., Newland N., Eldridge A., Graff D., Meyer I. A single-blinded, single-centre, controlled study in healthy adult smokers to identify the effects of a reduced toxicant prototype cigarette on biomarkers of exposure and of biological effect versus commercial cigarettes. BMC Public Health 2013, 13:690.
62. Stratton K., Shetty P., Wallace R., Bondurant S. Clearing the smoke: assessing the science base for tobacco harm reduction 2001, National Academy Press, Washington, DC.
63. Urban M., Gilch G., Schepers G., van Miert E., Scherer G. Determination of the major mercapturic acids of 1, 3-butadiene in human and rat urine using liquid chromatography with tandem mass spectrometry. J. Chromatogr. B 2003, 796(1):131-140.
64. van Sittert N.J. N-2-Cyanoethylvaline, N-2-Hydroxyethylvaline, N-Methylvaline (as evidence of exposure to acrylonitrile, ethylene oxide as well as methylating agents). Biomonitoring Methods 1996, vol. 5:181-219. Wiley-VCH, Weinheim.
65. Wennmalm A., Benthin G., Granstrom E., Persson L., Petersson A.S., Winell S. Relation between Tobacco use and urinary excretion of thromboxane A2 and prostcyclin metabolites in young men. Circulation 1991, 83:1698-1704.
66. World Health Organization The Tobacco Atlas. First Edition 2002, 90-91.
67. World Health Organization WHO report on the global tobacco epidemic: warning about the dangers of tobacco 2011, WHO Press, Geneva.